Johnson & Johnson (JNJ)vsNeuphoria Therapeutics Inc (NEUP)
JNJ
Johnson & Johnson
$229.85
+1.10%
HEALTHCARE · Cap: $547.28B
NEUP
Neuphoria Therapeutics Inc
$5.27
+1.54%
HEALTHCARE · Cap: $27.76M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 642883% more annual revenue ($96.36B vs $14.99M). JNJ leads profitability with a 21.8% profit margin vs -37.8%. JNJ earns a higher WallStSmart Score of 59/100 (C).
JNJ
Buy59
out of 100
Grade: C
NEUP
Avoid33
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-43.5%
Fair Value
$160.13
Current Price
$229.85
$69.72 premium
Margin of Safety
+66.4%
Fair Value
$11.93
Current Price
$5.27
$6.66 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -26.1% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bull Case : NEUP
The strongest argument for NEUP centers on Price/Book, Debt/Equity.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : NEUP
The primary concerns for NEUP are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
JNJ profiles as a mature stock while NEUP is a turnaround play — different risk/reward profiles.
JNJ is growing revenue faster at 9.9% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
JNJ scores higher overall (59/100 vs 33/100), backed by strong 21.8% margins. NEUP offers better value entry with a 66.4% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Neuphoria Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Neuphoria Therapeutics Inc (Ticker: NEUP) is a pioneering biotechnology firm focused on developing groundbreaking therapies for mental health disorders through the use of psychedelic compounds and innovative drug delivery mechanisms. The company is dedicated to translating advanced research into effective treatments for significant unmet needs within the mental health space, thereby positioning itself as a frontrunner in the burgeoning psychedelic therapy market. With a strong pipeline of preclinical candidates, Neuphoria represents a compelling investment opportunity for institutional investors keen on engaging with emerging biotech trends poised to reshape mental health care. Its commitment to transformative therapeutic solutions underscores its potential to significantly impact the future landscape of mental health treatment.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?